Theralase Technologies Inc. V.TLT

Interesting

[Alamir1111]

Fellowship designed to support the development of outstanding clinical cancer research investigators to improve the understanding and treatment of NMIBC

SCHAUMBURG, Ill. and IRVINE, Calif., Dec. 06, 2024 (GLOBE NEWSWIRE) -- The Society of Urologic Oncology Clinical Trials Consortium (SUO-CTC), a national alliance of leading academic and community based uro-oncologists, and CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced the first annual CG-SUO-CTC NMIBC Research Fellowship designed to support the development of outstanding clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).

“There remains a significant unmet need for treating NMIBC, and this fellowship will help advance research and drive innovation, leading to improvements in patient care,” said Sia Daneshmand, MD, Director of Urologic Oncology at USC/Norris Comprehensive Cancer Center and Chair of the Bladder Cancer Committee of the SUO-CTC.

Colin Dinney, MD, Chairman, Department of Urology, Division of Surgery, University of Texas MD Anderson Cancer Center, continued, “We are fortunate to have a very bright and motivated next generation of urologists coming into the field, and this is a great opportunity for them to collaborate with their mentors and present it at a prominent forum like AUA in 2026.”

“CG Oncology is honored to partner with the SUO-CTC on this important fellowship,” said Ambaw Bellete, President & Chief Operating Officer, CG Oncology. “We share a commitment to ultimately deliver better quality of life to patients with urologic cancers. This fellowship is another important step that will advance research and ultimately help patients.”

To apply for this fellowship, investigators may be working in basic, translational and clinical research fields, and they must be working in a research environment capable of supporting transformational NMIBC research. All applications are due by Friday, February 28, 2025, at 5:00 PM U.S. Eastern Time. Applications will be evaluated on the quality of the applicant’s proposed research plan and the resources and environment available to the applicant.

The award start date will be in May 2025 and the Award recipient will present their research results at the conclusion of the Award at SUO Meeting at the AUA in April/May 2026.

[Legit62]

Wait until they see our treatment in action!!!!!!!!

[CAinPlap]

As a competitor CG Oncology is a sponsor, could Theralase apply? or is this more aimed at Dr McFarlane?

[Infinity]

The way I read it the fellowship is offered by SUO and CTC.  CG oncology may have applied to participate or co-sponsor the CTC.  Not even sure if TLT Wanted to get in on this CTC.  Here is the link for the offer https://suoctc.org/about/links/suo-ctc-cg-oncology-nmibc-fellowship.aspx

[rollthedice10]

I just hope our various patents are secure and more pending. Just say'in

[Infinity]

I would like you understand some basic differences.  CG Oncology was founded in 2010.  I believe as a Delaware corp and held privately.  CG Oncology received Fast Track Designation and BTD at the same time beginning of 2024. CG oncology immediately decide to go Public via a modest IPO of 20 Million shares at USD $19.00  and raised $380 Million.  The IPO was managed by

[Oilminerdeluxe]

If I am not mistaken, that company is run by a billionaire, so money and connections with like minded investors have never been an issue for them.

[Longholder99]

If it wasn't for the extended timeframe Theralase has taken to bring this oncology solution from petri dishes to people walking around with healthy bladders who were previously scheduled to have those same bladders removed to prevent cancer from spreading to the rest of their body.  Many of us small time retailers who aren't friends with billionaires, would have never had a chance to

[Oilminerdeluxe]

With a little luck, TLT will have its talk with the FDA this month. If they don't delay us, the BTD application should be sent in. Not sure if it needs to take the full 60 days to approve or not, since they must be quite familiar by now about the data TLT is giving them. 

[Infinity]

Oilminer.  CGON was properly funded  raising over $300 Million by venture capitalists lead by ORI Capital.  This allowed them to remain privately held till they got the Fast Track and BTD at the same time.  On the same they issued the IPO which was oversubscribed in Jan 2024. These are the list of Venture capitalist.  We can claim that our Ruvidar is superior.  But we

[Infinity]

I would like you understand some basic differences.@ CG Oncology was founded in 2010.@ I believe as a Delaware corp and held privately.@ CG Oncology received Fast Track Designation and BTD at the same time beginning of 2024. CG oncology immediately decide to go Public via a modest IPO of 20 Million shares at USD $19.00@ and raised $380 Million.@ The IPO was managed by Morgan stanley and Goldman

[bmk211]

CG oncology posts a high CR rate.   Is there something I am missing with their data?  Is it treating all NMIBC or is this the company that has specific genes that are pre screened?

[Maxcitrac]

Yes bmk211 there is something you are missing, every two weeks somebody come back and post about CG Oncology and pretend that it is better than Ruvidar. No it is not. Study Details | Study of Cretostimogene Given in Patients With Non-Muscle Invasive Bladder Cancer ,Unresponsive to Bacillus-Calmette-Guerin | ClinicalTrials.gov Check under HOW THE STUDY IS DESIGNED. And try to calculate the number

[bmk211]

Wow that is an absurd amount of treatments.

[Eoganacht]

It's also important to remember that CG Oncology only treats patients who exhibit the "retinoblastoma negative protein" which only occurs in 25% of the high grade patient population. In other words, those high CR numbers only apply to 25% of the patients Theralase is treating. The remaining 75% Theralase can treat and CG Oncology can't. And, of course, Theralase only requires

[bmk211]

Great thank you.  That was the information I wanted to confirm.  

[Infinity]

Eoganacht,  I have always liked your more rational posts backed by science and logic.  I am going to throw in a completely unrelated analogy.   I AGREE we have a much better PLANE, more safer, more fuel efficient (less expensive) and Easy to operate.  CGON's plane has limitations on usage, more expensive to operate, probably less safer.   CGON simply has

[Maxcitrac]

Infinity you should check if there is a pilot in your brain. CGOncology has been a private company for 70% of its history. After a merger in 2021, CGON went public at a starting SP of almost $30.00. If Theralase had been a private company for 70% of its history and after going public, had a starting SP price of $30.00, none of the longs on this board would have been able to accumulate a sizable

[Infinity]

Maxi,  By all means keep drumming up whatever is in your brains.  At some point you need to understand the real difference between good prudent management and Micro Management.  Try and rationalise the difference, if you can, between a company struggling for a PP at pennies and (Having a better cure for cancer) being over subsubscribed at USD $ 19.00. (Having a limited or more

[Oilminerdeluxe]

Infinity, I agree that it would be much nicer if TLT had a big bag of cash to run things, but that should happen if we get BTD. The latest 1,5 years of delay were due to the FDA wanting more data (if I am not mistaken) and that's where we sort of got shafted for being void of cash. I think the way they have done things the last few years has been the best option. If a big fish had wanted to

[Mikee3003]

Great analogy Infinity!

[Maxcitrac]

Our no=2 basher, the Lunatic Airplane Pilot,  Nincompoop being n=1, The Lunatic Airplane Pilot(Infinity), has a twin on TLT reddit. Important_Stick_3194, wrote on TLT reddit '' CGON response rate is 75% in the first year''. DD - Theralase Technologies - Phase II clinical trial. Cancer food. Near term catalyst? : r/pennystocks Infinity you failed to explain why after CGON

[Infinity]

Maxi You are inhaling some good stuff.  Read again what I posted.  We do have a better cure and CGON has the advantage of more prudent Management as welll venture capitalist backing them.  Instead of relying on PP for pennies.  Get over it.  I have a substantial stake in TLT.  I don't have single share in CGON.  I stand to gain if this thing gets going after

[N0taP00p]

@Infinity:  Best to put him/her on ignore.  Neither logic nor light penetrate dense matter. There's a few here.  Was initially hoping today's volume was based on an info  leak.  But could be the Reddit thing as well. Let's hope to hear something good in a few weeks.  Please God, not another penny raise. 

[CAinPlap]

Maybe we should give Elon Musk a TLT investor started kit of say 50K shares and see how much faster things progress. ;)

[DeathXray33]

Slick-Con: The world's greatest engine oil treatment & dual purpose wall washer. Sick-Con: So slippery, not even James Bond can stick to them...